ATE448003T1 - Verwendung von substituierten 1,2,3-indolizin- derivaten zur behandlung von krankheiten im zusammenhang mit einer pathologischen angiogenese - Google Patents

Verwendung von substituierten 1,2,3-indolizin- derivaten zur behandlung von krankheiten im zusammenhang mit einer pathologischen angiogenese

Info

Publication number
ATE448003T1
ATE448003T1 AT05717556T AT05717556T ATE448003T1 AT E448003 T1 ATE448003 T1 AT E448003T1 AT 05717556 T AT05717556 T AT 05717556T AT 05717556 T AT05717556 T AT 05717556T AT E448003 T1 ATE448003 T1 AT E448003T1
Authority
AT
Austria
Prior art keywords
alk
alkyl
alkoxy
coor
carboxy
Prior art date
Application number
AT05717556T
Other languages
English (en)
Inventor
Alain Badorc
Francoise Bono
Marie-Francoise Bordes
Jean-Michel Foidart
Nathalie Guillo
Agnes Noel
Jean-Marie Rakic
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE448003T1 publication Critical patent/ATE448003T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
AT05717556T 2004-02-05 2005-02-04 Verwendung von substituierten 1,2,3-indolizin- derivaten zur behandlung von krankheiten im zusammenhang mit einer pathologischen angiogenese ATE448003T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0401094A FR2865934B1 (fr) 2004-02-05 2004-02-05 Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
PCT/FR2005/000253 WO2005082457A2 (fr) 2004-02-05 2005-02-04 Utilisation de derives d’indolizine 1,2,3 substitues pour le traitement de maladies liees à une angiogenese pathologique choroïdienne.

Publications (1)

Publication Number Publication Date
ATE448003T1 true ATE448003T1 (de) 2009-11-15

Family

ID=34778525

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05717556T ATE448003T1 (de) 2004-02-05 2005-02-04 Verwendung von substituierten 1,2,3-indolizin- derivaten zur behandlung von krankheiten im zusammenhang mit einer pathologischen angiogenese

Country Status (21)

Country Link
US (1) US8034828B2 (de)
EP (1) EP1713543B1 (de)
JP (1) JP5268258B2 (de)
KR (1) KR101199730B1 (de)
CN (1) CN1917922B (de)
AT (1) ATE448003T1 (de)
AU (1) AU2005216671B2 (de)
BR (1) BRPI0507509A (de)
CA (1) CA2553895C (de)
CY (1) CY1109669T1 (de)
DE (1) DE602005017581D1 (de)
DK (1) DK1713543T3 (de)
ES (1) ES2335900T3 (de)
FR (1) FR2865934B1 (de)
HK (1) HK1101065A1 (de)
HR (1) HRP20100030T1 (de)
IL (1) IL177088A (de)
PL (1) PL1713543T3 (de)
PT (1) PT1713543E (de)
SI (1) SI1713543T1 (de)
WO (1) WO2005082457A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2223925A1 (de) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase-Inhibitoren
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
EP2270043A1 (de) * 2009-07-03 2011-01-05 Sanofi-Aventis Extrazelluläre allosterische Inhibitorbindungsdomäne aus einem Tyrosinkinaserezeptor
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf

Also Published As

Publication number Publication date
HRP20100030T1 (hr) 2010-03-31
IL177088A (en) 2010-12-30
WO2005082457A3 (fr) 2005-11-10
JP5268258B2 (ja) 2013-08-21
AU2005216671A1 (en) 2005-09-09
JP2007520534A (ja) 2007-07-26
SI1713543T1 (sl) 2010-03-31
FR2865934B1 (fr) 2006-05-05
DK1713543T3 (da) 2010-03-22
FR2865934A1 (fr) 2005-08-12
EP1713543B1 (de) 2009-11-11
PL1713543T3 (pl) 2010-04-30
US8034828B2 (en) 2011-10-11
CN1917922B (zh) 2013-06-12
PT1713543E (pt) 2009-12-15
DE602005017581D1 (de) 2009-12-24
ES2335900T3 (es) 2010-04-06
US20090030034A1 (en) 2009-01-29
HK1101065A1 (de) 2007-10-05
IL177088A0 (en) 2006-12-10
WO2005082457A2 (fr) 2005-09-09
EP1713543A2 (de) 2006-10-25
AU2005216671B2 (en) 2010-09-16
CA2553895C (fr) 2013-04-02
KR20070034986A (ko) 2007-03-29
KR101199730B1 (ko) 2012-11-08
CN1917922A (zh) 2007-02-21
BRPI0507509A (pt) 2007-06-26
CY1109669T1 (el) 2014-08-13
CA2553895A1 (fr) 2005-09-09

Similar Documents

Publication Publication Date Title
CY1109669T1 (el) Χρηση υποκατεστημενων παραγωγων της ινδολιζινης 1,2,3 για τη θεραπεια νοσων που σχετιζονται με μια παθολογικη χοριοειδη αγγειογενεση
BRPI0513750A (pt) 2-fenilamino-benzamidas-5-substituìdas como inibidoras de mek
PE20030581A1 (es) Composiciones polimeras de liberacion controlada de compuestos que promueven el crecimiento oseo
CY1107853T1 (el) Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων
ATE450514T1 (de) Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung
RU2002124873A (ru) Глюкопиранозилоксибензилбензольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для получения указанных производных
MX2023013080A (es) Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
MX2022015703A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
DE602004005502D1 (de) Comt-inhibitoren
WO2007099302A8 (en) Methods of maintaining oral health in animals using morpholine derivatives
CY1109546T1 (el) Φαρμακο για την προληψη η θεραπεια της συχνουριας η της ουρικης ακρατειας
DE60127535D1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
DE60130030D1 (de) Verfahren zur behandlung von glaukom
DE60126199D1 (de) Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
RU2009138028A (ru) Новое профилактическое и/или лекарственное средство против невропатической боли
HK1080768A1 (en) Use of epothilone derivatives for the treatment ofhyperparathyroidism
TW200509917A (en) Use of growth hormone secretagogues for treatment of fibromyalgia
WO2008099853A1 (ja) 歯周組織再生促進用医薬組成物及び歯周組織再生促進剤

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1713543

Country of ref document: EP